The pharmacological management of erectile dysfunction
Keywords: cardiovascular disease, erectile dysfunction, phosphodiesterase-5 inhibitors, prostaglandin, testosterone
AbstractThe inability to attain or maintain a penile erection sufficient for sexual intercourse is a common problem experienced by a third of men over the age of 40 years. Erectile dysfunction (ED) is a debilitating disease which can have profound psychological effects on personal relationships and the social well-being of the affected individual. The diagnosis and evaluation of sexual dysfunction has been well described, and several validated algorithms are available to quantify the classification and severity. The International Index of Erectile Function and the Sexual Health Inventory for Men questionnaires are commonly used in the initial assessment of ED. Several risk factors have been linked to the pathophysiology of ED. Endothelial damage has been the focus of many recent studies. An evaluation of cardiovascular status, in addition to the administration of questionnaires to men with ED, might reduce mortality and improve sexual quality of life.
Material submitted for publication in the Journal of Endocrinology, Metabolism and Diabetes of South Africa (JEMDSA) is accepted provided it has not been published elsewhere. JEMDSA reserves copyright of the material published. Neither JEMDSA nor the Publisher may be held responsible for statements made by the authors.